Samsung Bioepis has become the latest firm to win a European Medicines Agency endorsement for an ustekinumab biosimilar, after the firm’s SB17 proposed rival to Stelara won a positive opinion from the agency’s Committee for Medicinal Products for Human Use.
Samsung Bioepis And Sandoz Get EU Nod For Stelara Rival
CHMP Positive Opinion Issued For Pyzchiva Ustekinumab Biosimilar And Accord Generics
Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.
